Insider Sell Alert: Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc (TRDA)

Author's Avatar
Dec 04, 2024

On December 3, 2024, Natarajan Sethuraman, President, Research & Development at Entrada Therapeutics Inc (TRDA, Financial), executed a sale of 15,891 shares of the company. Following this transaction, the insider now holds 144,997 shares of the company. The details of this transaction can be found in the SEC Filing. Entrada Therapeutics Inc (TRDA) is a biotechnology company focused on developing novel therapeutics for the treatment of rare diseases. The company leverages its proprietary Endosomal Escape Vehicle (EEV) technology to deliver a wide range of therapeutics intracellularly, aiming to address unmet medical needs. 1864128162418552832.png Over the past year, Natarajan Sethuraman has sold a total of 62,279 shares and has not made any purchases. The insider transaction history for Entrada Therapeutics Inc indicates a total of 6 insider buys and 23 insider sells over the same period. On the day of the recent sale, shares of Entrada Therapeutics Inc were trading at $20.18 each, resulting in a market cap of $754.761 million. The company's price-earnings ratio stands at 12.78, which is lower than the industry median of 26.78 but higher than the company’s historical median price-earnings ratio.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.